Want to join the conversation?
$CELG received FDA approval for POMALYST label update in patients with renal impairment. Abraxane net sales outside the US grew 2% YoverY, excluding the impact of FX and despite some slight headwind from price and distributor buying patterns.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.